Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives $14.28 Consensus Price Target from Brokerages

Niagen Bioscience, Inc. (NASDAQ:NAGE) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $14.2750.

Several brokerages recently weighed in on NAGE. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Canaccord Genuity Group dropped their price target on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th.

Niagen Bioscience Stock Performance

Niagen Bioscience stock opened at $5.99 on Friday. Niagen Bioscience has a 1 year low of $5.25 and a 1 year high of $14.69. The firm has a 50 day moving average price of $6.46 and a 200 day moving average price of $7.90. The company has a market cap of $478.06 million, a price-to-earnings ratio of 24.96 and a beta of 2.35.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $33.99 million for the quarter, compared to the consensus estimate of $31.30 million. Niagen Bioscience had a net margin of 16.38% and a return on equity of 24.13%.

Insider Buying and Selling

In other Niagen Bioscience news, CFO Ozan Pamir purchased 4,465 shares of Niagen Bioscience stock in a transaction on Friday, November 14th. The shares were purchased at an average cost of $6.81 per share, with a total value of $30,406.65. Following the completion of the transaction, the chief financial officer directly owned 7,372 shares in the company, valued at approximately $50,203.32. This represents a 153.59% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 9.39% of the company’s stock.

Hedge Funds Weigh In On Niagen Bioscience

A number of hedge funds have recently made changes to their positions in the business. New York State Teachers Retirement System purchased a new stake in Niagen Bioscience during the 4th quarter worth $30,000. Financial Consulate Inc. acquired a new position in shares of Niagen Bioscience during the third quarter worth about $33,000. State of Alaska Department of Revenue purchased a new stake in shares of Niagen Bioscience in the third quarter worth about $44,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Niagen Bioscience in the third quarter valued at about $45,000. Finally, North Star Investment Management Corp. acquired a new stake in shares of Niagen Bioscience in the third quarter valued at about $47,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.